CYP2C76, a novel cytochrome P450 in cynomolgus monkey, is a major CYP2C in liver, metabolizing tolbutamide and testosterone
Y Uno, H Fujino, G Kito, T Kamataki, R Nagata - Molecular pharmacology, 2006 - ASPET
Monkeys are widely used as a primate model to study drug metabolism because they
generally show a metabolic pattern similar to humans. However, the paucity of information on …
generally show a metabolic pattern similar to humans. However, the paucity of information on …
Transporter-mediated influx and efflux mechanisms of pitavastatin, a new inhibitor of HMG-CoA reductase
H Fujino, T Saito, S Ogawa… - Journal of pharmacy and …, 2005 - academic.oup.com
The purpose of this study was to gain a better understanding of the transport mechanism of
pitavastatin, a novel synthetic HMG-CoA reductase inhibitor. Experiments were performed …
pitavastatin, a novel synthetic HMG-CoA reductase inhibitor. Experiments were performed …
Effects of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYP-mediated metabolism and MDR1-mediated transport
T Sakaeda, H Fujino, C Komoto, M Kakumoto… - Pharmaceutical …, 2006 - Springer
Purpose With the growing clinical usage of 3-hydroxy-3-methylglutaryl coenzyme A reductase
inhibitors (statins), the number of reports concerning serious drug–drug interaction has …
inhibitors (statins), the number of reports concerning serious drug–drug interaction has …
Effect of lipopolysaccharide on the xenobiotic-induced expression and activity of hepatic cytochrome P450 in mice
N Moriya, H Kataoka, H Fujino, J Nishikawa… - Biological and …, 2012 - jstage.jst.go.jp
Cyp2b10. To assess the CYP enzymatic activities, CYP3A-mediated testosterone 6β-hydroxylation
and the intrinsic clearance (CLint) of nifedipine in liver microsomes were measured in …
and the intrinsic clearance (CLint) of nifedipine in liver microsomes were measured in …
Metabolic fate of pitavastatin (NK-104), a new inhibitor of 3-hydroxy-3-methyllutaryl coenzyme A reductase
H Fujino, I Yamada, S Shimada, T Nagao… - …, 2002 - thieme-connect.com
Pitavastatin (CAS 147526-32-7, NK-104) is a new and very potent competitive inhibitor of 3-hydroxy-3-methylglutaryl
coenzyme A (HMG-CoA) reductase and has been approved for …
coenzyme A (HMG-CoA) reductase and has been approved for …
Simultaneous determination of NK-104 and its lactone in biological samples by column-switching high-performance liquid chromatography with ultraviolet detection
J Kojima, H Fujino, M Yosimura, H Morikawa… - … of Chromatography B …, 1999 - Elsevier
A simple and sensitive column-switching HPLC method has been developed for the
simultaneous determination of NK-104 (HMG–CoA reductase inhibitor) and its lactone in human …
simultaneous determination of NK-104 (HMG–CoA reductase inhibitor) and its lactone in human …
Studies on the metabolic fate of NK-104, a new inhibitor of HMG-CoA reductase (1): Absorption, distribution, metabolism and excretion in rats
H KIMATA, H FUJINO, T KOIDE, Y YAMADA… - Drug Metabolism and …, 1998 - jstage.jst.go.jp
NK-104 is a synthetic inhibitor of 3 hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase
with very potent lipid-lowering effect. Absorption, distribution, metabolism and excretion …
with very potent lipid-lowering effect. Absorption, distribution, metabolism and excretion …
Studies on the metabolic fate of NK-104, a new inhibitor of HMG-CoA reductase (4): interspecies variation in laboratory animals and humans
H FuJINO, J KOJIMA, Y YAMADA, H KANDA… - Drug Metabolism and …, 1999 - jstage.jst.go.jp
NK-104 is a very potent competitive inhibitor of HMG-CoA reductase. The pharmacokinetic
properties of NK-104 were evaluated after intravenous and/or oral administration to rats, …
properties of NK-104 were evaluated after intravenous and/or oral administration to rats, …
Studies on the metabolic fate of NK-104, a new inhibitor of HMG-CoA reductase (5): in vitro metabolism and plasma protein binding in animals and human
H FUJINO, I YAMADA, J KOJIMA… - Drug Metabolism and …, 1999 - jstage.jst.go.jp
NK-104 is a new and very potent competitive inhibitor of HMG-CoA reductase. NK-104 bound
to plasma protein of mouse, rat, rabbit, dog and monkey, at a binding ratio of more than 96…
to plasma protein of mouse, rat, rabbit, dog and monkey, at a binding ratio of more than 96…
CYP2C76-mediated species difference in drug metabolism: A comparison of pitavastatin metabolism between monkeys and humans
…, T Kumano, G Kito, R Nagata, T Kamataki, H Fujino - Xenobiotica, 2007 - Taylor & Francis
The monkey is often used to predict metabolism of drugs in humans since it generally shows
a metabolic pattern similar to humans. However, metabolic profiles different from humans …
a metabolic pattern similar to humans. However, metabolic profiles different from humans …